This RFI seeks information on next-generation immunoassay technologies for high-performance antigen testing in near-patient settings, addressing current limitations in sensitivity and multiplexing compared to NAATs. No specific budget amounts are mentioned. No performance location is specified. No submission or non-bid timelines are provided. The opportunity is relevant for firms developing advanced antigen diagnostics for early infection detection and syndromic panels.